Losartan in diabetic nephropathy (Q57703074)

Expert Review of Cardiovascular Therapy

Europe PubMed Central

title

Losartan in diabetic nephropathy (English)

0 references

1 reference

1 reference

Giuseppe Remuzzi

3

0 references

Piero Ruggenenti

series ordinal

2

object named as

Piero Ruggenenti

0 references

Norberto Perico

series ordinal

1

object named as

Norberto Perico

0 references

publication date

July 2004

0 references

published in

0 references

volume

2

0 references

issue

4

0 references

page(s)

473-483

0 references

cites work

The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Prognosis in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Pathophysiology of Progressive Nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Proteinuria and phenotypic change of proximal tubular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Proteinuria and the risk of developing end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Progression of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Retarding progression of chronic renal disease: the neglected issue of residual proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Activation of a local tissue angiotensin system in podocytes by mechanical strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Angiotensin II depolarizes podocytes in the intact glomerulus of the Rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Angiotensin II as a mediator of tubulointerstitial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Interstitial pathomechanisms underlying progressive tubulointerstitial damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Vasoactive hormones and renal sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Losartan: a review of its use, with special focus on elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Pharmacokinetics and blood pressure response of losartan in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Losartan titration versus diuretic combination in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Optimal dose of losartan for renoprotection in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Progression, remission, regression of chronic renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Smoking as a risk factor for end-stage renal failure in men with primary renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Beneficial effects of water-based exercise in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473

Angiotensin II Induces alpha3(IV) Collagen Expression in Cultured Murine Proximal Tubular Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.4.473